Lamivudin/Zidovudin Puren

Lamivudine/Zidovudine, the active ingredient in Lamivudin/Zidovudin Puren, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as a tablet for oral use. It is employed in the management of HIV‑1 infection in adults and children, typically as part of a combination antiretroviral regimen to suppress viral replication and improve immune function.

GNH USA supplies Lamivudin/Zidovudin Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudin/Zidovudin Puren is an antiretroviral medication that targets the HIV replication pathway.

- HIV‑1 infection (adults): suppresses viral replication and increases CD4+ cell counts. - HIV‑1 infection (children): reduces viral load and supports immune development. - HIV‑1 infection (as part of combination therapy): enhances overall treatment efficacy when used with other antiretrovirals.

Adverse reactions may occur with any antiretroviral regimen.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Fatigue: general tiredness. - Anemia: reduced red blood cell count. - Diarrhea: loose stools. - Neutropenia: lowered neutrophil levels.

Serious or Rare Side Effects: - Severe anemia: may require transfusion. - Lactic acidosis: rare metabolic disturbance. - Hypersensitivity reactions: rash, fever, organ involvement. - Hepatotoxicity: elevated liver enzymes. - Bone marrow suppression: pancytopenia. - Pancreatitis: abdominal pain with elevated enzymes.

Use of Lamivudin/Zidovudin Puren requires careful clinical monitoring. - Renal function: assess baseline kidney function and monitor periodically. - Hepatic function: evaluate liver enzymes before and during therapy. - Hematologic status: perform regular complete blood counts to detect anemia or neutropenia. - Pregnancy: prescribe only when potential benefits outweigh risks. - Drug resistance: avoid monotherapy to prevent emergence of resistant HIV strains. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lamivudin/Zidovudin Puren can interact with several concomitant medications.

Major Interactions (Avoid): - Didanosine: increased risk of severe toxicity. - Stavudine: heightened mitochondrial toxicity. - Alcohol: may exacerbate liver injury.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs: monitor renal parameters. - Anticoagulants (e.g., warfarin): may affect INR levels. - Protease inhibitors: can alter plasma concentrations of lamivudine and zidovudine.